Compare DENTSPLY SIRONA Inc (XRAY) vs Xylem, Inc. (XYL) Price & Performance

DENTSPLY SIRONA (XRAY) trades at $11.40, down 2.23% amid ongoing revenue declines and negative profitability. The stock shows bearish technical signals with support at $11 and resistance at $12. Recent Q2 2026 earnings beat expectations with $0.52 EPS but revenue fell 4.1% year-over-year to $898 million, reflecting persistent challenges in dental markets. The company maintains a 'Hold' analyst consensus with a $11.50 price target while executing its turnaround strategy.

Investment outlook remains cautious given six consecutive quarters of revenue declines and negative net margins. The company's restructuring efforts and new CFO appointment offer potential for operational improvement, but weak European demand and competitive pressures pose significant headwinds. With debt-to-asset ratio rising to 42.88% in 2025, financial leverage adds risk to the recovery thesis.

Xylem (XYL) trades at $121.19, up 0.72% today, with a bullish technical trend and strong fundamental performance. The company reported Q2 2026 EPS of $1.46, beating estimates, and raised full-year profit guidance. Revenue growth is steady, with a net income margin of 11.15% in 2025. Recent acquisitions, like Cornell Pump and Roper Pump, aim to strengthen its industrial water technology presence. The stock shows bullish moving averages but a neutral RSI, with key resistance at $123.

Outlook remains positive due to earnings beats, margin expansion, and strategic acquisitions. Risks include execution of integration and macroeconomic pressures. Analyst consensus is a buy with a $150.43 price target, implying significant upside. Institutional activity is mixed, with some funds increasing stakes while others reduced holdings.